Skip to main content
Erschienen in: Breast Cancer 6/2016

22.10.2015 | Original Article

Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis

verfasst von: Takahisa Imamura, Mutsuko Yamamoto-Ibusuki, Aiko Sueta, Tatsuko Kubo, Atsushi Irie, Ken Kikuchi, Toru Kariu, Hirotaka Iwase

Erschienen in: Breast Cancer | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Emerging evidence has shown activation of the complement system in cancer tissues and anaphylatoxin C5a release from C5 by cancer cells, suggesting C5a as a component in the cancer microenvironment. We revealed aberrant expression of C5a receptor (C5aR) in various human cancers and C5a-elicited enhancement of C5aR-expressing cancer cell invasion.

Methods

To explore an influence of the C5a–C5aR system in breast cancer (BC), we investigated BC C5aR expression in relation to clinicopathological parameters of the patients and an effect of C5a on BC cell proliferation.

Results

BC cell C5aR expression was observed immunohistochemically in 22 of 171 patients (13 %) and related to larger tumor size, higher nuclear grade and Ki-67 labeling index, presence of lymph node metastasis and advanced clinical stages. Interestingly, BC cells were C5aR-negative in all patients with BC in situ and C5aR-positive rate was high (38 %) in patients with hormone receptor-negative, namely triple-negative BC. For BC cells in metastasized lymph nodes, 12 of 22 patients (55 %) were C5aR-positive and included 7 patients with C5aR-negative BC in the primary site. Survival rate of patients with C5aR-positive BC was lower than that of patients with C5aR-negative BC. C5a enhanced proliferation of C5aR-expressing triple-negative BC cells in a C5aR-dependent manner.

Conclusion

Relation of BC C5aR expression to tumor development and poor prognosis of the patients and proliferation enhancing effect of C5a on C5aR-expressing BC cells suggest that the C5a–C5aR system is closely associated with BC progression. This system may be a new target to treat BC patients, particularly with triple-negative BC.
Literatur
1.
Zurück zum Zitat Siegel R, Naishadham MA, Jemal ADV. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMed Siegel R, Naishadham MA, Jemal ADV. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.CrossRefPubMed
4.
Zurück zum Zitat Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–92.CrossRefPubMed Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–92.CrossRefPubMed
5.
Zurück zum Zitat Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, et al. Clinicopathological analyses of triple negative breast cancer using surveyance data from the Registration Committee of the Japanese breast cancer society. Breast Cancer. 2010;17:118–24.CrossRefPubMed Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, et al. Clinicopathological analyses of triple negative breast cancer using surveyance data from the Registration Committee of the Japanese breast cancer society. Breast Cancer. 2010;17:118–24.CrossRefPubMed
6.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative BC. Clinical features and patterns of recurrence. Cin Cancer Res. 2007;13:4429–34.CrossRef Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative BC. Clinical features and patterns of recurrence. Cin Cancer Res. 2007;13:4429–34.CrossRef
7.
Zurück zum Zitat DiScipio RG, Smith CA, Müller-Eberhard HJ, Hugli TE. The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem. 1983;258:10629–36.PubMed DiScipio RG, Smith CA, Müller-Eberhard HJ, Hugli TE. The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem. 1983;258:10629–36.PubMed
8.
9.
Zurück zum Zitat Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171:715–27.CrossRefPubMedPubMedCentral Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 2007;171:715–27.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in BC. Am J Pathol. 1992;140:1039–43.PubMedPubMedCentral Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in BC. Am J Pathol. 1992;140:1039–43.PubMedPubMedCentral
11.
Zurück zum Zitat Bjørge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE, et al. Ascitic complement system in ovarial cancer. Br J Cancer. 2005;92:895–905.CrossRefPubMedPubMedCentral Bjørge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE, et al. Ascitic complement system in ovarial cancer. Br J Cancer. 2005;92:895–905.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–35.CrossRefPubMedPubMedCentral Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–35.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 2012;186:4674–83.CrossRef Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol. 2012;186:4674–83.CrossRef
14.
Zurück zum Zitat Nitta H, Murakami Y, Wada Y, Eto M, Baba H, Imamura T. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep. 2014;32:1715–9.PubMed Nitta H, Murakami Y, Wada Y, Eto M, Baba H, Imamura T. Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncol Rep. 2014;32:1715–9.PubMed
15.
Zurück zum Zitat Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 2013;19:2004–13.CrossRefPubMed Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 2013;19:2004–13.CrossRefPubMed
16.
Zurück zum Zitat Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, K1-67 and the corresponding gene expression score in breast cancer. Modern Pathol. 2013;26:79–86.CrossRef Yamamoto-Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Fu P, et al. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, K1-67 and the corresponding gene expression score in breast cancer. Modern Pathol. 2013;26:79–86.CrossRef
17.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402–8.CrossRefPubMed Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402–8.CrossRefPubMed
18.
Zurück zum Zitat Finn RS, Dering J, Conklin D, Kalous O, Cohen D, Desai A, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.CrossRefPubMedPubMedCentral Finn RS, Dering J, Conklin D, Kalous O, Cohen D, Desai A, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat van de Vijer MJ. Molecular tests as prognostic factors in breast cancer. Virchows Arch. 2014;464:283–91.CrossRef van de Vijer MJ. Molecular tests as prognostic factors in breast cancer. Virchows Arch. 2014;464:283–91.CrossRef
20.
Zurück zum Zitat Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11:643–58.CrossRefPubMed Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11:643–58.CrossRefPubMed
21.
Zurück zum Zitat Valabrega G, Montemurro F, Sarotto I, Petorelli A, Rubini P, Tacchetti C, et al. TGFα expression impairs trastuzumab-induced HER2 downregulation. Oncogene. 2005;24:3002–10.CrossRefPubMed Valabrega G, Montemurro F, Sarotto I, Petorelli A, Rubini P, Tacchetti C, et al. TGFα expression impairs trastuzumab-induced HER2 downregulation. Oncogene. 2005;24:3002–10.CrossRefPubMed
23.
Zurück zum Zitat Gu J, Ding J-Y, Lu C-L, Lin Z-W, Chu Y-W, Zhao G-Y, et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013;81:259–65.CrossRefPubMed Gu J, Ding J-Y, Lu C-L, Lin Z-W, Chu Y-W, Zhao G-Y, et al. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013;81:259–65.CrossRefPubMed
24.
Zurück zum Zitat Cai K, Wan Y, Wang Z, Wang Y, Zhao XJ, Bao XL. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation. Oncol Rep. 2014;32:2260–6.PubMed Cai K, Wan Y, Wang Z, Wang Y, Zhao XJ, Bao XL. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation. Oncol Rep. 2014;32:2260–6.PubMed
25.
Zurück zum Zitat Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T. Relation of anaphylatoxin C5a receptor (CD88) expression of urothelial cancer to poor prognosis of patients treated by radical cystectomy or nephro-ureterectomy. Oncol Lett 2015; (in press). Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T. Relation of anaphylatoxin C5a receptor (CD88) expression of urothelial cancer to poor prognosis of patients treated by radical cystectomy or nephro-ureterectomy. Oncol Lett 2015; (in press).
26.
Zurück zum Zitat Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014;6:1–11.CrossRef Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014;6:1–11.CrossRef
27.
Zurück zum Zitat Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol. 1994;12:775–808.CrossRefPubMed Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol. 1994;12:775–808.CrossRefPubMed
28.
Zurück zum Zitat Müller A, Homey H, Soto H, Ge N, Carton D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.CrossRefPubMed Müller A, Homey H, Soto H, Ge N, Carton D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–6.CrossRefPubMed
29.
Zurück zum Zitat Roland J, Murphy BJ, Ahr B, Robert-Hebmann V, Delauzun V, Ke Nye, et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood. 2003;101:399–406.CrossRefPubMed Roland J, Murphy BJ, Ahr B, Robert-Hebmann V, Delauzun V, Ke Nye, et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood. 2003;101:399–406.CrossRefPubMed
30.
Zurück zum Zitat Sun X, Wei L, Chen Q, Terek RM. CXCR4/SDF-1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer. 2010;9:17.CrossRefPubMedPubMedCentral Sun X, Wei L, Chen Q, Terek RM. CXCR4/SDF-1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer. 2010;9:17.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep. 2015;33:1844–50.PubMed Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep. 2015;33:1844–50.PubMed
32.
Zurück zum Zitat Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967–71.PubMedPubMedCentral Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967–71.PubMedPubMedCentral
33.
Zurück zum Zitat Sobolik T, Sun YJ, Wells S, Ayers GD, Cook RS, Richmond A. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3 pathways. Mol Biol Cell. 2014;25:566–82.CrossRefPubMedPubMedCentral Sobolik T, Sun YJ, Wells S, Ayers GD, Cook RS, Richmond A. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3 pathways. Mol Biol Cell. 2014;25:566–82.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24:7443–54.CrossRefPubMed Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24:7443–54.CrossRefPubMed
35.
Zurück zum Zitat Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The elevated levels of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast. 2005;14:360–7.CrossRefPubMed Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. The elevated levels of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast. 2005;14:360–7.CrossRefPubMed
36.
Zurück zum Zitat Su YC, Wu MT, Huang CJ, Hou MF, Yang SF, Chai CY. Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. The Breast. 2006;15:533–9.CrossRefPubMed Su YC, Wu MT, Huang CJ, Hou MF, Yang SF, Chai CY. Expression of CXCR4 is associated with axillary lymph node status in patients with early breast cancer. The Breast. 2006;15:533–9.CrossRefPubMed
37.
Zurück zum Zitat Hasaan S, Buchanan M, Jahan K, Aguila-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011;129:225–32.CrossRef Hasaan S, Buchanan M, Jahan K, Aguila-Mahecha A, Gaboury L, Muller WJ, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011;129:225–32.CrossRef
38.
Zurück zum Zitat Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, et al. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS ONE. 2013;8:e58426.CrossRefPubMedPubMedCentral Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, et al. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS ONE. 2013;8:e58426.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastasis. Proc Natl Acad Sci USA. 2013;110:E1291–300.CrossRefPubMedPubMedCentral Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastasis. Proc Natl Acad Sci USA. 2013;110:E1291–300.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175:4583–92.CrossRefPubMedPubMedCentral Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175:4583–92.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Nozawa H, Chiu C, Hanahan D. Infiltrating neutrons mediate the initial angiogenic switch in a mouse model of multi-stage carcinogenesis. Proc Natl Acad Sci USA. 2006;103:12493–8.CrossRefPubMedPubMedCentral Nozawa H, Chiu C, Hanahan D. Infiltrating neutrons mediate the initial angiogenic switch in a mouse model of multi-stage carcinogenesis. Proc Natl Acad Sci USA. 2006;103:12493–8.CrossRefPubMedPubMedCentral
Metadaten
Titel
Influence of the C5a–C5a receptor system on breast cancer progression and patient prognosis
verfasst von
Takahisa Imamura
Mutsuko Yamamoto-Ibusuki
Aiko Sueta
Tatsuko Kubo
Atsushi Irie
Ken Kikuchi
Toru Kariu
Hirotaka Iwase
Publikationsdatum
22.10.2015
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 6/2016
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-015-0654-3

Weitere Artikel der Ausgabe 6/2016

Breast Cancer 6/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.